NZ255732A - Composition for inhibiting cell proliferation using apoliprotein e (apoe) - Google Patents

Composition for inhibiting cell proliferation using apoliprotein e (apoe)

Info

Publication number
NZ255732A
NZ255732A NZ255732A NZ25573293A NZ255732A NZ 255732 A NZ255732 A NZ 255732A NZ 255732 A NZ255732 A NZ 255732A NZ 25573293 A NZ25573293 A NZ 25573293A NZ 255732 A NZ255732 A NZ 255732A
Authority
NZ
New Zealand
Prior art keywords
apoe
cells
proliferation
fcs
cell
Prior art date
Application number
NZ255732A
Other languages
English (en)
Inventor
Tikva Vogel
Amos Panet
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Publication of NZ255732A publication Critical patent/NZ255732A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ255732A 1992-08-12 1993-08-12 Composition for inhibiting cell proliferation using apoliprotein e (apoe) NZ255732A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92897992A 1992-08-12 1992-08-12

Publications (1)

Publication Number Publication Date
NZ255732A true NZ255732A (en) 1997-05-26

Family

ID=25457115

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ255732A NZ255732A (en) 1992-08-12 1993-08-12 Composition for inhibiting cell proliferation using apoliprotein e (apoe)

Country Status (9)

Country Link
EP (1) EP0659085A4 (ja)
JP (1) JPH08502730A (ja)
KR (1) KR950702430A (ja)
AU (1) AU673543B2 (ja)
CA (1) CA2141598A1 (ja)
IL (1) IL106664A0 (ja)
NZ (1) NZ255732A (ja)
WO (1) WO1994004178A1 (ja)
ZA (1) ZA935879B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
IL110638A0 (en) * 1993-08-12 1994-11-11 Bio Technology General Corp Composition for inhibiting kaposi's sarcoma
IL120005A (en) * 1997-01-14 2000-08-31 Ramot University Authority Of Pharmaceutical compositions for the treatment of the eye
US6593291B1 (en) * 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
AU4449900A (en) * 1999-03-17 2000-10-04 Entremed, Inc Compositions and methods of use of ldl-like receptor ligands for the treatment of cancer and angiogenic-based disease
WO2001037853A2 (en) * 1999-11-23 2001-05-31 North Shore - Long Island Jewish Health System Methods and agents for the inhibition of smooth muscle cell proliferation
US20020182587A1 (en) * 2001-03-02 2002-12-05 Sivaram Pillarisetti Methods and compositions for the treatment and prevention of smooth muscle cell proliferation
CN102137680A (zh) * 2008-07-01 2011-07-27 克格诺西有限公司 用apoe肽治疗癌症的方法
CA2823191A1 (en) 2010-01-06 2011-07-14 Cognosci, Inc. Apoe peptide dimers and uses thereof
WO2013042684A1 (ja) * 2011-09-20 2013-03-28 国立大学法人熊本大学 リポ蛋白を用いた神経疾患予防・治療剤ならびに神経疾患予防・治療方法
WO2022059703A1 (ja) * 2020-09-16 2022-03-24 国立大学法人大阪大学 がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168045A (en) * 1989-08-18 1992-12-01 The Scripps Research Institute Diagnostic systems and methods using polypeptide analogs of apolipoprotein e
US5473039A (en) * 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
AU658578B2 (en) * 1991-06-26 1995-04-27 Bio-Technology General Corporation Purification of recombinant apolipoprotein E from bacteria
IL110638A0 (en) * 1993-08-12 1994-11-11 Bio Technology General Corp Composition for inhibiting kaposi's sarcoma

Also Published As

Publication number Publication date
ZA935879B (en) 1994-03-11
JPH08502730A (ja) 1996-03-26
KR950702430A (ko) 1995-07-29
EP0659085A4 (en) 1996-06-12
IL106664A0 (en) 1993-12-08
EP0659085A1 (en) 1995-06-28
AU673543B2 (en) 1996-11-14
AU5007293A (en) 1994-03-15
CA2141598A1 (en) 1994-03-03
WO1994004178A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
Kume et al. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells.
US5284827A (en) Systemic treatment of metastatic cancer with platelet factor 4
AU710061B2 (en) Amphipathic molecules as cholesterol and other lipid uptake inhibitors
EP0407122A1 (en) Novel modified PF4 compositions and methods of use
AU673543B2 (en) Method of inhibiting cell proliferation using apolipoprotein E
US5869055A (en) Anti-inflammatory CD14 polypeptides
EP1599173B1 (en) Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
CA2361612A1 (en) Peptides modulating activities of heparin, other glycosaminoglycans or proteoglycans
EP1357930B1 (en) Histidine-rich glycoprotein (hrgp) for inhibiting angiogenesis
RU2164414C2 (ru) Подавление роста опухолевых клеток эктодоменом синдекана-1
AU711586B2 (en) Mocarhagin, a cobra venom protease, and therapeutic uses thereof
MXPA00011398A (es) Analogo de remocion de proteina que incrementa la actividad bactericida/permeabilidad (bpi).
US20140171365A1 (en) Pegylated human hdl particle and process for production thereof
AU691085B2 (en) Anti-inflammatory CD14 polypeptides
NZ225940A (en) Interleukin-1 inhibitors (il-1 inh) and pharmaceutical compositions
JP3030386B2 (ja) 抗ガン剤
US5942220A (en) Inhibitor of cytokine activity and applications thereof
EP0580752A1 (en) Human bone derived insulin like growth factor binding protein
WO1993013794A1 (en) Novel methods and compositions for treatment of angiogenic diseases
US5770561A (en) Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1991012334A1 (en) Inhibitor of cytokine activity and applications thereof
Knight et al. Low apparent affinity for low‐density lipoprotein of receptors expressed by human macrophages maintained with whole serum
JP2002528058A (ja) コントートロスタチン（ｃｎ）、並びに転移及び他の症状の抑制におけるその使用方法
EP0715521A1 (en) Method of inhibiting kaposi's sarcoma
EP0560998A1 (en) Medicine for preventing and treating bleeding tendency